# Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia

> **NCT01313689** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 122 (actual)

## Conditions studied

- Leukaemia

## Interventions

- **DRUG:** Ofatumumab
- **DRUG:** Physicians' Choice

## Key facts

- **NCT ID:** NCT01313689
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-14
- **Primary completion:** 2014-03-18
- **Final completion:** 2017-04-24
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2018-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01313689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01313689, "Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01313689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*